SQZ Biotechnologies Company logo
SQZ Biotechnologies Company SQZ

Quarterly report 2023-Q3
added 11-08-2023

report update icon

SQZ Biotechnologies Company Financial Ratios 2011-2026 | SQZ

Annual Financial Ratios SQZ Biotechnologies Company

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-0.2 -3.6 -6.9 - - - - - - - - -

P/S

0.8 9.1 16.5 - - - - - - - - -

EPS

-2.8 -2.5 -9.3 -18.9 - - - - - - - -

EV (Enterprise Value)

-3.96 M 205 M 280 M 184 M 159 M - - - - - - -

EBITDA per Share

-2.75 -2.45 -2.78 - - - - - - - - -

EV/EBITDA

-2.7 -4.6 - - - - - - - - -

PEG

- 0.12 - - - - - - - - -

P/B

0.3 2.0 2.7 - - - - - - - - -

P/CF

-0.2 -3.0 -7.8 - - - - - - - - -

ROE %

-139.05 -55.45 -39.72 - - - - - - - - -

ROA %

-79.54 -30.40 -21.86 - - - - - - - - -

ROCE %

-141.18 -55.47 -27.46 - - - - - - - - -

Current Ratio

2.3 2.2 3.9 - - - - - - - - -

DSO

- 32.9 42.4 - - - - - - - - -

Operating Cycle

- 33.0 - - - - - - - - - -

Cash Conversion Cycle

- 33.0 - - - - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios SQZ Biotechnologies Company

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.8 -0.57 -0.6 - -0.77 -0.78 -0.75 - -0.8 -0.68 -0.59 - -7.03 -5.74 -6.09 - -4.58 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

-0.8 -0.57 -0.61 - -0.78 -0.78 -0.74 - -0.79 -0.67 -0.57 - -6.88 -5.63 -6.11 - -4.63 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

-1402.14 -178.43 -135.30 -78.29 -95.14 -78.97 -66.25 -38.44 -48.15 -41.00 -36.37 -25.88 -15.16 5.28 13.13 10.72 10.72 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-149.13 -84.39 -63.90 -35.58 -44.77 -28.87 -36.87 -23.05 -28.39 -24.54 -20.87 -14.24 -19.42 -19.25 -14.93 -5.17 -5.17 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

-1414.20 -182.55 -138.34 -79.27 -96.13 -79.30 -66.28 -38.45 -48.20 -41.09 -36.53 -26.29 -14.90 6.24 14.17 11.39 11.39 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

1.1 1.8 2.2 2.3 1.8 - 2.1 2.2 2.2 2.8 2.8 2.2 2.2 2.2 2.2 1.6 1.6 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DSO

- - - - - - 47.7 - - - 15.8 - 28.2 28.9 26.8 - 20.4 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

- - - - - - 47.7 - - - 15.8 - 28.2 28.9 26.8 - 20.4 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

- - - - - - 47.7 - - - 15.8 - 28.2 28.9 26.8 - 20.4 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company SQZ Biotechnologies Company, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 3.78 - $ 105 M schweizSchweiz
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.35 -2.17 % $ 347 M usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 3.5 -21.7 % $ 236 B britainBritain
Aldeyra Therapeutics Aldeyra Therapeutics
ALDX
$ 1.58 -4.82 % $ 94.9 M usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 8.36 4.89 % $ 82.6 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 330.71 3.72 % $ 43.3 B usaUSA
Altimmune Altimmune
ALT
$ 3.47 3.89 % $ 306 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
$ 1.98 0.25 % $ 106 M usaUSA
Amgen Amgen
AMGN
$ 346.45 -0.43 % $ 186 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 12.37 -0.92 % $ 3.88 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Anika Therapeutics Anika Therapeutics
ANIK
$ 15.0 1.32 % $ 220 M usaUSA
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
$ 76.34 2.87 % $ 1.47 B usaUSA
Annexon Annexon
ANNX
$ 5.64 2.45 % $ 875 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.92 -1.11 % $ 5.02 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Aprea Therapeutics Aprea Therapeutics
APRE
$ 0.73 2.63 % $ 4.77 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.15 0.48 % $ 444 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 8.43 4.98 % $ 231 M israelIsrael
Ardelyx Ardelyx
ARDX
$ 6.08 2.27 % $ 1.47 B usaUSA
argenx SE argenx SE
ARGX
$ 752.05 0.75 % $ 25 B niderlandNiderland
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.93 1.27 % $ 3.04 B usaUSA
Arvinas Arvinas
ARVN
$ 11.11 2.4 % $ 788 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 61.57 0.88 % $ 8.24 B usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
$ 30.01 3.43 % $ 336 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
$ 1.14 16.28 % $ 35.6 M usaUSA
Atossa Therapeutics Atossa Therapeutics
ATOS
$ 5.21 -2.89 % $ 44.9 M usaUSA
Atara Biotherapeutics Atara Biotherapeutics
ATRA
$ 5.03 0.7 % $ 63.1 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 16.04 2.75 % $ 2.16 B canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.42 0.35 % $ 378 M britainBritain
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA